Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza a virus subtype H1N1 with the H274Y mutation: A Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons

Clinical Infectious Diseases

Volumn 49, Issue 12, 2009, Pages 1828-1835

  Kawai, Naoki ^a,c   Lkematsu, Hideyuki ^a,b   Hirotsu, Nobuo ^a   Maeda, Tetsunari ^a   Kawashima, Takashi ^a   Tanaka, Osame ^a   Yamauchi, Satoshi ^a   Kawamura, Kenichi ^a   Matsuura, Shinro ^a   Nishimura, Mika ^b   Iwaki, Norio ^a   Kashiwagi, Seizaburo ^a  

^a Japan Physician's Association   (Japan)

^b Hara Doi Hospital   (Japan)

^c Kawai Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ADULT; ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; FEMALE; FEVER; GENE MUTATION; GENE SEQUENCE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYMPTOM; TREATMENT RESPONSE; VIRUS ISOLATION;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; FEVER; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MUTATION; NEURAMINIDASE; OSELTAMIVIR; TIME FACTORS; ZANAMIVIR;

EID: 72049128868     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648424     Document Type: Article

References (23)

1. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir 2008-2009 influenza season. Available at: http://www.who.int/csr/ disease/influenza/H1lN120090122-final.pdf. Accessed 3 No-vember 2009.
2. Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivirresistant influenza virus neuraminidase mutants. Nature 2008; 453: 1258-1261
3. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:pii:8026.
4. Kawai N, Ikematsu H, Iwaki N, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005; 40:1309-1316
5. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439-444
6. Kawai N, Ikematsu H, Iwaki N, et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J Infect 2007; 55:267-272
7. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect 2008; 56:51-57 (Pubitemid 350258321)
8. Kawai N, Ikematsu H, Iwaki N, et al. A change in the effectiveness of amantadine for the treatment of influenza over the 2003-2004, 2004-2005, and 2005-2006 influenza seasons in Japan. J Infect Chemother 2007; 13:314-319
9. Kawai N, Ikematsu H, Iwaki N, et al. Comparison of the effectiveness of zanamivir and oseltamivir against influenza A/H1N1, A/H3N2, and B. Clin Infect Dis 2009; 48:996-997
10. Kawai N, Ikematsu H, Iwaki N, et al. A prospective, Internet-based study of the effectiveness and safety of influenza vaccination in the 2001-2002 influenza season. Vaccine 2003; 21:4507-4513
11. Kawai N, Ikematsu H, Iwaki N, et al. Zanamivir treatment is equally effective for both influenza A and influenza B. Clin Infect Dis 2007; 44:1666. (Pubitemid 46871519)
12. Kawai N, Ikematsu H, Iwaki N, et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect 2009; 59:207-212
13. Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 2002; 54:143-147 (Pubitemid 34327680)
14. OoC,BarrettJ,HillG,etal. Pharmacokineticsanddosagerecommendationsforanoseltamiviroralsuspensionforthet reatmentofinfluenzainchildren.PaediatricDrugs2001;3:229-236(Pubitemid32250938)
15. McClellanK,PerryCM.Oseltamivir:areviewofitsuseininfluenza.Drugs2001;61: 263-283(Pubitemid32210201)
16. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-764
17. Gooskens J, Jonges M, Claas ECJ, et al. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009; 199:1435-1441
18. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza a viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-765 (Pubitemid 39165094)
19. van der Vries E, van den Berg B, Schutten M. Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 2008; 359:1074-1076
20. Gooskens J, Jonges M, Claas EC, et al. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 2009; 301:1066-1069
21. Centers for Disease Control and Prevention. Issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A(H1N1) viruses, 2008-09 Influenza Season. Health Alert Network, December 19, 2008. Available at: http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum = 00279. Accessed 3 November 2009.
22. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953-956
23. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivirresistant influenza A(H1N1) virus in the United States. JAMA 2009; 301:1066-1069